August 12, 2018 | Press Release

FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies

July 25, 2018 | Press Release

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)

July 19, 2018 | Press Release

Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)

July 18, 2018 | Press Release

Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer

July 17, 2018 | Press Release

FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

July 16, 2018 | Press Release

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

July 11, 2018 | Press Release

Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

July 1, 2018 | Press Release

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer

June 25, 2018 | Press Release

FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza

June 24, 2018 | Press Release

Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy

June 13, 2018 | News Feature

FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery

On June 13, 2018 the FDA approved a Genentech medicine for the treatment of women with advanced (stage III or IV) epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection.

View information and materials

June 13, 2018 | Press Release

FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery

June 13, 2018 | Press Release

Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS

June 8, 2018 | News Feature

FDA Approves New Treatment Option for Previously Treated Chronic Lymphocytic Leukemia

On June 8, 2018, the FDA approved a Genentech medicine for people with previously treated chronic lymphocytic leukemia.

View information and materials

June 8, 2018 | Press Release

Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia

June 7, 2018 | Press Release

FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris

June 4, 2018 | Press Release

FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors

June 2, 2018 | Press Release

Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer

May 28, 2018 | Press Release

Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone

May 20, 2018 | Press Release

Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors

May 16, 2018 | Press Release

Follow-Up Phase III Data Showed Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

May 16, 2018 | Press Release

Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel

May 14, 2018 | Press Release

FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis

May 13, 2018 | Press Release

Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress

May 9, 2018 | Press Release

Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer

May 7, 2018 | Press Release

Genentech to Present New Data From Its Industry-Leading Oncology Portfolio at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 6, 2018 | Press Release

FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

December 20, 2017 | News Feature

FDA Approves New Treatment Option for Adjuvant Treatment of Specific Type of Early Breast Cancer

On December 20, 2017, the FDA approved a Genentech medicine for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence.

View information and materials

November 16, 2017 | News Feature

FDA Approves New Once-Weekly Prophylactic Treatment For Hemophilia A With Inhibitors

On November 16, the FDA approved a Genentech medicine as a prophylactic (preventative) treatment for adults and children with hemophilia A with factor VIII inhibitors that can be self-administered once weekly by injection under the skin (subcutaneously).

View information and materials

November 16, 2017 | News Feature

FDA Approves New Treatment Option for Previously Untreated Advanced Follicular Lymphoma

On November 16, 2017, the FDA approved a Genentech medicine as a treatment option for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).

View information and materials

November 6, 2017 | News Feature

FDA Approves Genentech Medicine for First-Line Treatment of Specific Type of Lung Cancer

On November 6, 2017, the FDA approved a Genentech medicine for the treatment of people with a specific type of lung cancer.

View information and materials

June 22, 2017 | News Feature

FDA Approves New Time-Saving Treatment Option for People with Certain Blood Cancers

On June 22, 2017, the FDA approved a Genentech medicine for subcutaneous (under the skin) injection for the treatment of certain blood cancers.

View information and materials

April 17, 2017 | News Feature

FDA Approves New Option for Certain People with Advanced Bladder Cancer

On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.

View information and materials

April 17, 2017 | News Feature

FDA Approves New Treatment Option for People with Diabetic Retinopathy

On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.

View information and materials

March 28, 2017 | News Feature

FDA Approves New Medicine for Relapsing and Primary Progressive Forms of Multiple Sclerosis

On March 28, the FDA approved the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.

View information and materials

December 6, 2016 | News Feature

FDA Approves Medicine for Women with Platinum-Sensitive Recurrent Ovarian Cancer

On December 6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

View information and materials

October 18, 2016 | News Feature

FDA Approves New Immunotherapy Medicine for a Type of Metastatic Lung Cancer

On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.

View information and materials

September 16, 2016 | News Feature

Flu Season Resources

On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).

View information and materials

May 18, 2016 | News Feature

FDA Approves New Immunotherapy Medicine for Specific Type of Advanced Bladder Cancer

On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.

View information and materials

April 11, 2016 | News Feature

FDA Approves New Treatment Option for Hard-To-Treat Type of Chronic Lymphocytic Leukemia

On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.

View information and materials

February 26, 2016 | News Feature

FDA Approves New Option For Certain People With Previously Treated Follicular Lymphoma

On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.

View information and materials

December 11, 2015 | News Feature

FDA Approves New Treatment Option for Specific Type of Lung Cancer

On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.

View information and materials

November 10, 2015 | News Feature

FDA Approves New Treatment Option for Advanced Melanoma

On November 10, 2015, the FDA approved a new medicine for the treatment of advanced melanoma.

View information and materials

February 6, 2015 | News Feature

FDA Approves Genentech Medicine for Diabetic Retinopathy in People with Diabetic Macular Edema

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

View information and materials

November 14, 2014 | News Feature

FDA Approves Genentech Medicine for Women with Platinum-Resistant Recurrent Ovarian Cancer

On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.

View information and materials

October 15, 2014 | News Feature

FDA Approves Medicine for Idiopathic Pulmonary Fibrosis

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

View information and materials

August 14, 2014 | News Feature

FDA Approves Genentech Medicine for Women with Advanced Cervical Cancer

On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.

View information and materials

July 1, 2014 | News Feature

Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals

On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.

View information and materials

March 21, 2014 | News Feature

FDA Approves Xolair® (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.

View information and materials

December 5, 2013 | News Feature

ASH 2013: Press Releases, Fact Sheets & More

We're presenting important new findings on unapproved and investigational medicines at ASH 2013. Read press releases and learn about our presence at ASH this year.

View information and materials

November 1, 2013 | News Feature

FDA Approves New Genentech Medicine for Chronic Lymphocytic Leukemia (CLL)

On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.

View information and materials

May 15, 2013 | News Feature

2013 ASCO Annual Meeting

Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.

View information and materials

May 14, 2013 | News Feature

FDA Approves First Personalized Medicine for EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer in the United States

On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.

View information and materials

May 10, 2013 | News Feature

Celebrating the 60th Anniversary of Watson & Crick’s Discovery

Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.

View information and materials

January 23, 2013 | News Feature

FDA Approves New Use of Avastin Plus Fluoropyrimidine-Based Chemotherapy in Metastatic Colorectal Cancer

On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.

View information and materials

October 12, 2012 | News Feature

FDA Approves Expanded Indication for Actemra in RA

On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.

View information and materials

August 25, 2012 | News Feature

Genentech's gRide Program Achieves Landmark Milestone

gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.

View information and materials

August 10, 2012 | News Feature

Lucentis Approved for Treatment of Diabetic Macular Edema (DME)

On August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).

View information and materials

June 11, 2012 | News Feature

Genentech Gives Back Week 2012

Genentech Gives Back Week (June 11 - 16, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.

View information and materials

June 8, 2012 | News Feature

Perjeta Approved For HER2-Positive Metastatic Breast Cancer

On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.

View information and materials

May 30, 2012 | News Feature

Genentech at ASCO 2012

Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).

View information and materials

May 17, 2012 | News Feature

Landmark Alzheimer's Prevention Trial

Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.

View information and materials

January 30, 2012 | News Feature

Erivedge Approved For Advanced Basal Cell Carcinoma

On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

View information and materials

August 17, 2011 | News Feature

Genentech Medicine Approved For Certain Type Of Melanoma

On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.

View information and materials

October 20, 2010 | News Feature

Genentech Medicine Approved in Stomach Cancer

On October 20, 2010, a Genentech medicine was approved by the U.S. Food and Drug Administration (FDA) for stomach cancer.

View information and materials

October 18, 2010 | News Feature

25th Anniversary of First Product Approval

October 18, 2010 is the 25th anniversary of Genentech's first product approval and the first recombinant biotech drug to be manufactured and marketed by a biotechnology company.

View information and materials

September 21, 2010 | News Feature

Napoleone Ferrara Named 2010 Lasker Award Winner

Genentech Fellow Napoleone Ferrara is the winner of the 2010 Lasker Award for clinical research, presented annually to an investigator "whose contributions have improved the clinical treatment of patients."

View information and materials

September 13, 2010 | News Feature

Genentech Goes to Town 2010

Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.

View information and materials

June 14, 2010 | News Feature

Genentech Gives Back Week 2010

Genentech Gives Back Week voluntary activities each day that help Genentech employees collectively make a difference in our communities. All employees are invited to participate in Genentech Gives Back as their time and interest allows.

View information and materials